GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Net Change in Cash

VRAX (Virax Biolabs Group) Net Change in Cash : $2.18 Mil (TTM As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Virax Biolabs Group's Net Change in Cash for the six months ended in Sep. 2024 was $3.70 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 was $2.18 Mil.

Virax Biolabs Group Net Change in Cash Historical Data

The historical data trend for Virax Biolabs Group's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Net Change in Cash Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
Net Change in Cash
-0.04 -0.01 - 9.33 -5.76

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.55 4.96 -4.25 -1.52 3.70

Virax Biolabs Group Net Change in Cash Calculation

Virax Biolabs Group's Net Change in Cash for the fiscal year that ended in Mar. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-6.247+-1.164+1.648+0
=-5.76

Virax Biolabs Group's Net Change in Cash for the quarter that ended in Sep. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-1.919+-0.248+5.863+0
=3.70

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $2.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virax Biolabs Group Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Net Change in Cash
Comparable Companies
AEON ADIL ALZN KTTA CPMV AZTR BZYR SXTP CERO XBIO VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH
Website
https://www.viraxbiolabs.com
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.